Abstract
Humanized monoclonal antibodies to tumor necrosis factor- alpha are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 ("reversal") leprosy reactions.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / immunology
-
Antirheumatic Agents / therapeutic use
-
Arthritis / drug therapy*
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Infliximab
-
Leprostatic Agents / therapeutic use
-
Leprosy, Borderline / chemically induced
-
Leprosy, Borderline / etiology*
-
Leprosy, Borderline / microbiology
-
Male
-
Middle Aged
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Glucocorticoids
-
Leprostatic Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab